Ugandan Dr.Paul Semugoma, victory!

One of the studies that looked at the efficiency of a new three-drug combination, which included ABT450, Ritonavir and an NS5A inhibitor, found 97 per cent of patients had no trace of Hepatitis C twelve weeks after treatment.

A team of UCLA researchers have found that Twitter as well as other real-time social media tools can be extremely useful in tracking outbreaks of HIV and drug use

ViiV Healthcare’s single-tablet regimen Triumeq won Food and Drug Administration approval on August 22, 2014. Triumeq is the first FDA-approved single-tablet regimen (STR) that does not contain tenofovir (Viread), a widely used antiretroviral drug linked with bone and kidney problems in some susceptible HIV-positive individuals.